We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Treatment Decisions for Patients With Active Multiple Sclerosis

Olaf Stüve, MD, PhD1,2,3,4; Diego Centonze, MD, PhD5,6
[+] Author Affiliations
1Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas
2Neurology Section, VA North Texas Health Care System, Medical Service, Dallas
3Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
4Associate Editor, JAMA Neurology
5Department of Systems Medicine, Multiple Sclerosis Clinical and Research Center, Tor Vergata University and Hospital, Rome, Italy
6Istituto Di Ricovero e Cura a Carattere Scientifico, Fondazione Santa Lucia, Centro Europeo di Ricerca sul Cervello, Rome, Italy
JAMA Neurol. 2015;72(4):387-389. doi:10.1001/jamaneurol.2014.4494.
Text Size: A A A
Published online


In the complex scenario of current multiple sclerosis (MS) treatment options, it is becoming imperative for clinicians to have the instruments to make prompt treatment decisions for patients who have a suboptimal response, in order to avoid that the MS progresses to such an extent that any therapy adjustment would no longer be effective. How to modify treatment to achieve a better response can be a complex issue, and decisions should be made on the basis of a drug’s efficacy, safety, and tolerability. Before natalizumab and fingolimod were made available for the treatment of MS, many published experiences have tried to define the risks and advantages of switching among platform therapies (interferons to glatiramer acetate or vice versa). Overall, these studies show that switching among first-line therapies can be of some benefit in reducing disease activity, at least in the short term, for patients with breakthrough disease; however, the advantages of switching therapy owing to poor tolerability, and not to treatment failure, are less clear.1

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

2 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles